Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Liabilities and Shareholders Equity: 2011-2024

Historic Liabilities and Shareholders Equity for Niagen Bioscience (NAGE) over the last 11 years, with Dec 2024 value amounting to $68.3 million.

  • Niagen Bioscience's Liabilities and Shareholders Equity rose 73.63% to $98.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.3 million, marking a year-over-year increase of 54.50%. This contributed to the annual value of $68.3 million for FY2024, which is 24.22% up from last year.
  • Per Niagen Bioscience's latest filing, its Liabilities and Shareholders Equity stood at $68.3 million for FY2024, which was up 24.22% from $55.0 million recorded in FY2023.
  • Niagen Bioscience's Liabilities and Shareholders Equity's 5-year high stood at $68.3 million during FY2024, with a 5-year trough of $38.4 million in FY2020.
  • In the last 3 years, Niagen Bioscience's Liabilities and Shareholders Equity had a median value of $55.0 million in 2023 and averaged $59.1 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 50.79% in 2021, then dropped by 6.54% in 2022.
  • Over the past 5 years, Niagen Bioscience's Liabilities and Shareholders Equity (Yearly) stood at $38.4 million in 2020, then soared by 50.79% to $57.8 million in 2021, then fell by 6.54% to $54.1 million in 2022, then increased by 1.68% to $55.0 million in 2023, then increased by 24.22% to $68.3 million in 2024.